- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Hobert succeeds Kerpelman as head of Kodak’s Health Group
Kodak’s Health Group has a new head. On Feb.16, the company appointed Kevin J. Hobert president of the group and senior vice president of Eastman Kodak. He will report to Antonio M. Perez, Kodak’s president and COO.
Kodak's Health Group has a new head. On Feb.16, the company appointed Kevin J. Hobert president of the group and senior vice president of Eastman Kodak. He will report to Antonio M. Perez, Kodak's president and COO.
Hobert replaces Daniel Kerpelman, who is leaving the company to become CEO
of SGS Group, a publicly traded European firm. Kerpelman will assume his new duties April 11. SGS Group, founded in 1878, runs about 1000 offices and laboratories around the world specializing in inspection, verification, testing, and certification. Services are provided to a number of industries, including diagnostics.
Hobert previously served as general manager of Kodak's Digital Capture Systems and vice president of its Health Group. Under Hobert, Kodak's computed radiography business has attained the number two position worldwide, according to the company. Hobert also recently ushered Kodak's mammography CAD system through the FDA approval process.
Hobert joined Kodak in 2002 from GE Medical Systems, after 11 years in medical imaging. He was responsible for leading GEMS' global businesses addressing digital, analog and mobile radiography and multipurpose fluoroscopy. Hobert holds a bachelor of science in physics from the University of Wisconsin.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
